^
    7ms
    The effects of metformin and PCL-sorafenib nanoparticle co-treatment on MCF-7 cell culture model of breast cancer. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    In addition, they affected the expression of BCL2 and BAX genes and altered the cell cycle. Together, the combination of PCL-sorafenib/metformin and sorafenib/metformin increased sorafenib absorption at lower doses and also led to apoptosis and oxidative stress increases in MCF-7 cells.
    Preclinical • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • GPX4 (Glutathione Peroxidase 4) • ANXA5 (Annexin A5)
    |
    BCL2 expression • BAX expression • GPX4 expression
    |
    sorafenib • metformin • HyNap-Sora (sorafenib nanoparticle)
    over1year
    Microfluidics-enabled Serial Assembly of Lipid-siRNA-sorafenib Nanoparticles for Synergetic Hepatocellular Carcinoma Therapy. (PubMed, Adv Mater)
    In vivo, the LSS NPs delivering hypoxia-induced factor (HIF1?)-targeted siRNA efficiently regress tumors of Hep3B xenograft and hepatocellular carcinoma patient-derived primary cells xenograft (PDCX), and finally extend the average survival of PDCX mice to 68 days. Thus, our strategy is promising as a sorafenib/siRNA combination therapy and MESA can be a universal platform for fabricating complex nanosystems.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    sorafenib • HyNap-Sora (sorafenib nanoparticle)